✦ LIBER ✦

Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older

✍ Scribed by Gardin, C.; Chevret, S.; Pautas, C.; Turlure, P.; Raffoux, E.; Thomas, X.; Quesnel, B.; de Revel, T.; de Botton, S.; Gachard, N.; Renneville, A.; Boissel, N.; Preudhomme, C.; Terre, C.; Fenaux, P.; Bordessoule, D.; Celli-Lebras, K.; Castaigne, S.; Dombret, H.

Book ID: 126033761
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 184 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2011.40.3642

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term follow-up of three randomized

Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia

✍ Ellin Berman; Peter Wiernik; Ralph Vogler; Enrique Vélez-Gárcia; Alfred Bartoluc 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

BACKGROUND. Most clinical trials for acute leukemia have reported results after

Comparison of toxicity and outcome in pa

Comparison of toxicity and outcome in patients with acute myeloid leukemia treated with high-dose cytosine arabinoside consolidation after induction with a regimen containing idarubicin or daunorubicin

✍ G. Seipelt; W.-K. Hofmann; H. Martin; B. Wassmann; A. Boehme; O. G. Ottmann; D. 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 205 KB

Randomized study of induction therapy co

Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study

✍ Ohtake, S.; Miyawaki, S.; Fujita, H.; Kiyoi, H.; Shinagawa, K.; Usui, N.; Okumur 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 194 KB

Gemtuzumab ozogamicin with or without in

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside

✍ Estey, E. H. 📂 Article 📅 2002 🏛 American Society of Hematology 🌐 English ⚖ 84 KB

High-dose cytarabine induction is well t

High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years

✍ Martha Arellano; Elliott Winton; Lin Pan; Lisa Lima; Mourad Tighiouart; Kapil Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 1 views

Fractionated doses of gemtuzumab ozogami

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: A phase 1/2 study of the acute leukemia French association

✍ Hassan Farhat; Oumedaly Reman; Emmanuel Raffoux; Celine Berthon; Cécile Pautas; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views